Iranian Journal of Medical Sciences

Iranian Journal of Medical Sciences

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Journal Team

Publication Ethics

Indexing and Abstracting

Related Links

Peer Review Process

Journal Metrics

The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status

Document Type : Review Article

Authors

1 Department of Microbiology, Virology, and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

2 Department of Internal Diseases 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

3 Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhsta

Abstract

T-cell-mediated immunity is essential for controlling severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection, preventing severe disease, and potentially reducing the risk of long-term coronavirus disease (COVID). This study investigated the impact of natural infection, vaccination, and hybrid immunity on T-cell responses, with a particular emphasis on the role of memory T-cells in long-term COVID-19. The present study reviewed current literature on T-cell responses, including memory T-cell development, in individuals with natural SARS-CoV-2 infection, those vaccinated with messenger RNA (mRNA) vaccines, and those with hybrid immunity. It examined studies that compared T-cell activity, immune regulation, and the prevalence of long-term COVID-19 across these groups. Natural infection induces variable T-cell responses, with severe cases showing stronger but sometimes dysregulated immunological activity, which may contribute to prolonged COVID-19. Vaccination, particularly with mRNA vaccines, elicits targeted and consistent T-cell responses, including memory T-cells, reducing disease severity, and the incidence of long-term COVID-19. Hybrid immunity combines natural infection and vaccination, provides the most robust protection, enhanceds memory T-cell responses, and reduces the risk of long-term COVID-19 through balanced immune regulation. Memory T-cells play a critical role in mitigating long-term COVID-19. Vaccination significantly enhances T-cell-mediated immunity, minimizing the risk of chronic symptoms compared to natural infection alone. Hybrid immunity provides the most effective defense, emphasizing the importance of vaccination, even after natural infection, to prevent long-term COVID-19.

Keywords

References
  1. Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186-93. doi: 10.1038/s41590-021-01122-w. PubMed PMID: 35105982.
  2. Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8:235. doi: 10.1038/s41392-023-01471-y. PubMed PMID: 37332039; PubMed Central PMCID: PMCPMC10277291.
  3. Lu X, Yamasaki S. Current understanding of T cell immunity against SARS-CoV-2. Inflamm Regen. 2022;42:51. doi: 10.1186/s41232-022-00242-6. PubMed PMID: 36447270; PubMed Central PMCID: PMCPMC9706904.
  4. Tziolos NR, Ioannou P, Baliou S, Kofteridis DP. Long COVID-19 Pathophysiology: What Do We Know So Far? Microorganisms. 2023;11:2458. doi: 10.3390/microorganisms11102458. PubMed PMID: 37894116; PubMed Central PMCID: PMCPMC10609046.
  5. Dhawan M, Rabaan AA, Fawarah MMA, Almuthree SA, Alsubki RA, Alfaraj AH, et al. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines (Basel). 2023;11:101. doi: 10.3390/vaccines11010101. PubMed PMID: 36679947; PubMed Central PMCID: PMCPMC9861463.
  6. Bohmwald K, Diethelm-Varela B, Rodriguez-Guilarte L, Rivera T, Riedel CA, Gonzalez PA, et al. Pathophysiological, immunological, and inflammatory features of long COVID. Front Immunol. 2024;15:1341600. doi: 10.3389/fimmu.2024.1341600. PubMed PMID: 38482000; PubMed Central PMCID: PMCPMC10932978.
  7. Tarique M, Suhail M, Naz H, Muhammad N, Tabrez S, Zughaibi TA, et al. Where do T cell subsets stand in SARS-CoV-2 infection: an update. Frontiers in cellular and infection microbiology. 2022;12:964265. doi: 10.3389/fcimb.2022.964265. PubMed PMID: 36034704; PubMed Central PMCID: PMCPMC9399648.
  8. Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, et al. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv. 2023. doi: 10.1101/2023.02.09.527892. PubMed PMID: 36798286; PubMed Central PMCID: PMCPMC9934605.
  9. Sapir T, Averch Z, Lerman B, Bodzin A, Fishman Y, Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. Int J Mol Sci. 2022;23:8606. doi: 10.3390/ijms23158606. PubMed PMID: 35955740; PubMed Central PMCID: PMCPMC9369212.
  10. Pruner KB, Pepper M. Local memory CD4 T cell niches in respiratory viral infection. J Exp Med. 2021;218:e20201733. doi: 10.1084/jem.20201733. PubMed PMID: 34160551; PubMed Central PMCID: PMCPMC8225681.
  11. Hermens JM, Kesmir C. Role of T cells in severe COVID-19 disease, protection, and long term immunity. Immunogenetics. 2023;75:295-307. doi: 10.1007/s00251-023-01294-9. PubMed PMID: 36752852; PubMed Central PMCID: PMCPMC9905767.
  12. Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024;25:218-25. doi: 10.1038/s41590-023-01724-6. PubMed PMID: 38212464; PubMed Central PMCID: PMCPMC10834368.
  13. Yunis J, Short KR, Yu D. Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. Trends Microbiol. 2023;31:644-56. doi: 10.1016/j.tim.2022.12.008. PubMed PMID: 36635162; PubMed Central PMCID: PMCPMC9829516.
  14. Purbey PK, Roy K, Gupta S, Paul MK. Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. Mol Immunol. 2023;156:111-26. doi: 10.1016/j.molimm.2023.03.009. PubMed PMID: 36921486; PubMed Central PMCID: PMCPMC10009586.
  15. Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8(+) T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol. 2021;22:809-19. doi: 10.1038/s41590-021-00949-7. PubMed PMID: 34140679; PubMed Central PMCID: PMCPMC9197228.
  16. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4(+)T cells: differentiation and functions. Clin Dev Immunol. 2012;2012:925135. doi: 10.1155/2012/925135. PubMed PMID: 22474485; PubMed Central PMCID: PMCPMC3312336.
  17. Opsteen S, Files JK, Fram T, Erdmann N. The role of immune activation and antigen persistence in acute and long COVID. J Investig Med. 2023;71:545-62. doi: 10.1177/10815589231158041. PubMed PMID: 36879504; PubMed Central PMCID: PMCPMC9996119.
  18. Muller L, Di Benedetto S. From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity. Front Immunol. 2023;14:1298004. doi: 10.3389/fimmu.2023.1298004. PubMed PMID: 37942323; PubMed Central PMCID: PMCPMC10628127.
  19. Chaisawangwong W, Wang H, Kouo T, Salathe SF, Isser A, Bieler JG, et al. Cross-reactivity of SARS-CoV-2- and influenza A-specific T cells in individuals exposed to SARS-CoV-2. JCI Insight. 2022;7:e158308. doi: 10.1172/jci.insight.158308. PubMed PMID: 36134660; PubMed Central PMCID: PMCPMC9675569.
  20. Sealy RE, Hurwitz JL. Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study. Microorganisms. 2021;9:1643. doi: 10.3390/microorganisms9081643. PubMed PMID: 34442723; PubMed Central PMCID: PMCPMC8398386.
  21. Lesmes-Rodríguez LC, Lambarey H, Chetram A, Riou C, Wilkinson RJ, Joyimbana W, et al. Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa. Frontiers in Virology. 2023;3:1125448. doi: 10.3389/fviro.2023.1125448.
  22. da Silva Antunes R, Pallikkuth S, Williams E, Dawen Yu E, Mateus J, Quiambao L, et al. Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. J Infect Dis. 2021;224:70-80. doi: 10.1093/infdis/jiab176. PubMed PMID: 33822097; PubMed Central PMCID: PMCPMC8083569.
  23. Tan CCS, Owen CJ, Tham CYL, Bertoletti A, van Dorp L, Balloux F. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. Infect Genet Evol. 2021;95:105075. doi: 10.1016/j.meegid.2021.105075. PubMed PMID: 34509646; PubMed Central PMCID: PMCPMC8428999.
  24. Olukitibi TA, Ao Z, Warner B, Unat R, Kobasa D, Yao X. Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. Vaccines (Basel). 2023;11:545. doi: 10.3390/vaccines11030545. PubMed PMID: 36992129; PubMed Central PMCID: PMCPMC10056353.
  25. Murray SM, Ansari AM, Frater J, Klenerman P, Dunachie S, Barnes E, et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat Rev Immunol. 2023;23:304-16. doi: 10.1038/s41577-022-00809-x. PubMed PMID: 36539527; PubMed Central PMCID: PMCPMC9765363.
  26. Eggenhuizen PJ, Ooi JD. The Influence of Cross-Reactive T Cells in COVID-19. Biomedicines. 2024;12:564. doi: 10.3390/biomedicines12030564. PubMed PMID: 38540178; PubMed Central PMCID: PMCPMC10967880.
  27. Yang L, Caradonna TM, Schmidt AG, Chakraborty AK. Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens. Cell Rep. 2023;42:112160. doi: 10.1016/j.celrep.2023.112160. PubMed PMID: 36867533; PubMed Central PMCID: PMCPMC10184763.
  28. Echaide M, Chocarro de Erauso L, Bocanegra A, Blanco E, Kochan G, Escors D. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. Int J Mol Sci. 2023;24:5944. doi: 10.3390/ijms24065944. PubMed PMID: 36983017; PubMed Central PMCID: PMCPMC10051235.
  29. Tai W, Feng S, Chai B, Lu S, Zhao G, Chen D, et al. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nat Commun. 2023;14:2962. doi: 10.1038/s41467-023-38751-8. PubMed PMID: 37221158; PubMed Central PMCID: PMCPMC10204679.
  30. Spinardi JR, Srivastava A. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines. 2023;11:370. doi: 10.3390/biomedicines11020370. PubMed PMID: 36830907; PubMed Central PMCID: PMCPMC9953148.
  31. Wang L, Nicols A, Turtle L, Richter A, Duncan CJ, Dunachie SJ, et al. T cell immune memory after covid-19 and vaccination. BMJ Med. 2023;2:e000468. doi: 10.1136/bmjmed-2022-000468. PubMed PMID: 38027416; PubMed Central PMCID: PMCPMC10668147.
  32. Chen B, Julg B, Mohandas S, Bradfute SB, Force RMPT. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;12:e86015. doi: 10.7554/eLife.86015. PubMed PMID: 37140960; PubMed Central PMCID: PMCPMC10159620.
  33. Chen B, Julg B, Mohandas S, Bradfute SB. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;12. doi: 10.7554/eLife.86015. PubMed PMID: 37140960; PubMed Central PMCID: PMCPMC10159620.
  34. Rotrosen E, Kupper TS. Assessing the generation of tissue resident memory T cells by vaccines. Nat Rev Immunol. 2023;23:655-65. doi: 10.1038/s41577-023-00853-1. PubMed PMID: 37002288; PubMed Central PMCID: PMCPMC10064963.
  35. Hartley GE, Edwards ESJ, O’Hehir RE, van Zelm MC. New insights into human immune memory from SARS-CoV-2 infection and vaccination. Allergy. 2022;77:3553-66. doi: 10.1111/all.15502. PubMed PMID: 36048132; PubMed Central PMCID: PMCPMC9538469.
  36. Natalini A, Simonetti S, Sher C, D’Oro U, Hayday AC, Di Rosa F. Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. Int J Mol Sci. 2022;23:14367. doi: 10.3390/ijms232214367. PubMed PMID: 36430845; PubMed Central PMCID: PMCPMC9698736.
  37. Philpott JD, Miller J, Boribong BP, Charles S, Davis JP, Kazimierczyk S, et al. Antigen-specific T cell responses in SARS-CoV-2 mRNA-vaccinated children. Cell Rep Med. 2023;4:101298. doi: 10.1016/j.xcrm.2023.101298. PubMed PMID: 38016480; PubMed Central PMCID: PMCPMC10772322.
  38. Yin Z, Chen JL, Lu Y, Wang B, Godfrey L, Mentzer AJ, et al. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination. Cell Rep. 2023;42:112470. doi: 10.1016/j.celrep.2023.112470. PubMed PMID: 37141092; PubMed Central PMCID: PMCPMC10121105.
  39. Gilbert SC. T-cell-inducing vaccines - what’s the future. Immunology. 2012;135:19-26. doi: 10.1111/j.1365-2567.2011.03517.x. PubMed PMID: 22044118; PubMed Central PMCID: PMCPMC3246649.
  40. Fatima S, Ismail M, Ejaz T, Shah Z, Fatima S, Shahzaib M, et al. Association between long COVID and vaccination: A 12-month follow-up study in a low- to middle-income country. PLoS One. 2023;18:e0294780. doi: 10.1371/journal.pone.0294780. PubMed PMID: 37992084; PubMed Central PMCID: PMCPMC10664948.
  41. Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783-90. doi: 10.1016/j.vaccine.2023.02.008. PubMed PMID: 36774332; PubMed Central PMCID: PMCPMC9905096.
  42. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398:1377-80. doi: 10.1016/S0140-6736(21)02046-8. PubMed PMID: 34534516; PubMed Central PMCID: PMCPMC8437678.
  43. Gao F, Mallajosyula V, Arunachalam PS, van der Ploeg K, Manohar M, Roltgen K, et al. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8(+) T cell responses post SARS-CoV-2 infection. Immunity. 2023;56:864-78 e4. doi: 10.1016/j.immuni.2023.03.005. PubMed PMID: 36996809; PubMed Central PMCID: PMCPMC10017386.
  44. Jamous YF, Alhomoud DA. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2. Cureus. 2023;15:e45602. doi: 10.7759/cureus.45602. PubMed PMID: 37868494; PubMed Central PMCID: PMCPMC10588549.
  45. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021;162:30-43. doi: 10.1111/imm.13262. PubMed PMID: 32935333; PubMed Central PMCID: PMCPMC7730020.
  46. Skarke C, Lordan R, Barekat K, Naik A, Mathew D, Ohtani T, et al. Modulation of the Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination by Nonsteroidal Anti-Inflammatory Drugs. J Pharmacol Exp Ther. 2023;386:198-204. doi: 10.1124/jpet.122.001415. PubMed PMID: 37105582; PubMed Central PMCID: PMCPMC10353078.
  47. Abufares HI, Oyoun Alsoud L, Alqudah MAY, Shara M, Soares NC, Alzoubi KH, et al. COVID-19 Vaccines, Effectiveness, and Immune Responses. Int J Mol Sci. 2022;23:15415. doi: 10.3390/ijms232315415. PubMed PMID: 36499742; PubMed Central PMCID: PMCPMC9737588.
  48. Ozbay Kurt FG, Lepper A, Gerhards C, Roemer M, Lasser S, Arkhypov I, et al. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Front Immunol. 2022;13:1012526. doi: 10.3389/fimmu.2022.1012526. PubMed PMID: 36311732; PubMed Central PMCID: PMCPMC9597683.
  49. Lim JME, Hang SK, Hariharaputran S, Chia A, Tan N, Lee ES, et al. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines. Cell Rep Med. 2022;3:100793. doi: 10.1016/j.xcrm.2022.100793. PubMed PMID: 36257326; PubMed Central PMCID: PMCPMC9534788.
  50. Fraser R, Orta-Resendiz A, Mazein A, Dockrell DH. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends Mol Med. 2023;29:255-67. doi: 10.1016/j.molmed.2023.01.003. PubMed PMID: 36764906; PubMed Central PMCID: PMCPMC9868365.
  51. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43-55. doi: 10.1016/S1473-3099(21)00460-6. PubMed PMID: 34480857; PubMed Central PMCID: PMCPMC8409907.
  52. Mohan A, Iyer VA, Kumar D, Batra L, Dahiya P. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response. Life. 2023;13:2121. doi: 10.3390/life13112121. PubMed PMID: 38004261; PubMed Central PMCID: PMCPMC10672162.
  53. Diani S, Leonardi E, Cavezzi A, Ferrari S, Iacono O, Limoli A, et al. SARS-CoV-2-The Role of Natural Immunity: A Narrative Review. J Clin Med. 2022;11:6272. doi: 10.3390/jcm11216272. PubMed PMID: 36362500; PubMed Central PMCID: PMCPMC9655392.
  54. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine. 2023;95:104734. doi: 10.1016/j.ebiom.2023.104734. PubMed PMID: 37515986; PubMed Central PMCID: PMCPMC10404859.
  55. Cai C, Gao Y, Adamo S, Rivera-Ballesteros O, Hansson L, Osterborg A, et al. SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19. Sci Immunol. 2023;8:eadh0687. doi: 10.1126/sciimmunol.adh0687. PubMed PMID: 38064569; PubMed Central PMCID: PMCPMC7615587.
  56. Qui M, Hariharaputran S, Hang SK, Zhang J, Tan CW, Chong CY, et al. T cell hybrid immunity against SARS-CoV-2 in children: a longitudinal study. EBioMedicine. 2024;105:105203. doi: 10.1016/j.ebiom.2024.105203. PubMed PMID: 38896919; PubMed Central PMCID: PMCPMC11237860.
  57. Pitiriga VC, Papamentzelopoulou M, Konstantinakou KE, Theodoridou K, Vasileiou IV, Tsakris A. SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination. Vaccines (Basel). 2023;11:1186. doi: 10.3390/vaccines11071186. PubMed PMID: 37515000; PubMed Central PMCID: PMCPMC10384199.
  58. Maciel M, Jr., Amara RR, Bar KJ, Crotty S, Deeks SG, Duplessis C, et al. Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report. NPJ Vaccines. 2024;9:39. doi: 10.1038/s41541-024-00818-y. PubMed PMID: 38383616; PubMed Central PMCID: PMCPMC10881492.
  59. Jarupan M, Jantarabenjakul W, Jaruampornpan P, Subchartanan J, Phasomsap C, Sritammasiri T, et al. Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand. Vaccines (Basel). 2023;11:884. doi: 10.3390/vaccines11050884. PubMed PMID: 37242988; PubMed Central PMCID: PMCPMC10223729.
  60. Boretti A. mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review. Clin Exp Med. 2024;24:23. doi: 10.1007/s10238-023-01264-1. PubMed PMID: 38280109; PubMed Central PMCID: PMCPMC10821957.
  61. Castro Dopico X, Ols S, Lore K, Karlsson Hedestam GB. Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med. 2022;291:32-50. doi: 10.1111/joim.13372. PubMed PMID: 34352148; PubMed Central PMCID: PMCPMC8447342.
  62. Naaber P, Tserel L, Kangro K, Punapart M, Sepp E, Jurjenson V, et al. Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. Cell Rep Med. 2022;3:100716. doi: 10.1016/j.xcrm.2022.100716. PubMed PMID: 35952669; PubMed Central PMCID: PMCPMC9350667.
Iranian Journal of Medical Sciences
Volume 50, Issue 2
February 2025
Pages 61-68
Files
History
  • Received: 08 September 2024
  • Revised: 05 November 2024
  • Accepted: 26 November 2024
Share
How to cite
Statistics